Use of Otoscope as a Non-Invasive Tool for Diagnosis of Pilomatricoma
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Stanford University Dermatology Clinics and Lucile Packard Children's Hospital are evaluating the use of the otoscope for the diagnosis of skin lesions. We are particularly looking for children and/or adults with nodules, cysts, tumors, or pilomatricomas. The study will take 15-30 minutes and we will use light to examine and take a picture of your skin lesion. There is no monetary compensation for participating in the study.
| Condition |
|---|
|
Pilomatrixoma |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Use of Otoscope as a Non-Invasive Tool for Diagnosis of Pilomatricoma |
| Estimated Enrollment: | 30 |
| Study Start Date: | April 2008 |
| Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Pilomatricoma is a benign tumor that presents as a 3-30mm firm, solitary, deep dermal or subcutaneous tumor on the head, neck, or upper extremities. The clinical diagnosis is often made by the firm, sometimes rock hard texture of the skin. The diagnosis can be confirmed by a skin biopsy and/or excision of the lesion. We have recently noted that pilomatricomas appear as a black mass in the skin when the lesion is transilluminated by placing the light of a fiberoptic otoscope adjacent to the skin lesion. We would like to confirm our impression by a prospective study using transillumination to examine subcutaneous tumors in the skin. Pilomatricoma is also known as a benign calcifying or calcified epithelioma, pilomatrixoma, or a calcifying epithelioma of Malherbe.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:- Potential participants will be any patient that is seen at Stanford Dermatology or LPCH that has a cyst, nodule, vesicle, tumor, or possible pilomatricoma
Exclusion Criteria:- Inability of subject or subject's guardian to understand informed consent form.
Contacts and Locations| Contact: Emily S Gorell | (650) 721-7159 | egorell@stanford.edu |
| United States, California | |
| Stanford University School of Medicine | Recruiting |
| Stanford, California, United States, 94305 | |
| Contact: Emily S Gorell 650-721-7159 egorell@stanford.edu | |
| Principal Investigator: Odmara Liz Barreto-Chang | |
| Principal Investigator: Alfred T Lane | |
| Sub-Investigator: Hayes Gladstone | |
| Sub-Investigator: Anna L Bruckner | |
| Principal Investigator: | Alfred T Lane | Stanford University |
More Information
No publications provided
| Responsible Party: | Emily S Gorell |
| ClinicalTrials.gov Identifier: | NCT00715819 History of Changes |
| Other Study ID Numbers: | SU-07092008-1245, eProtocol #:13219 |
| Study First Received: | July 11, 2008 |
| Last Updated: | February 17, 2009 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Pilomatrixoma Neoplasms, Basal Cell Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms |
ClinicalTrials.gov processed this record on June 18, 2013